Literature DB >> 28075663

Comparative study of Her-2, p53, Ki-67 expression and clinicopathological characteristics of breast cancer in a cohort of northern China female patients.

Li Ding1, Zijin Zhang1, Yan Xu1, Yongqiang Zhang1.   

Abstract

The objective was to study the relationship among Her-2, Ki-67, p53 expression and the clinicopathologic characteristics of breast cancer in the patients of northern China. Expression of Her-2, Ki-67, p53 and clinical characteristics of 260 breast cancer patients were retrospectively studied. Her-2 overexpression led to higher incidence rates of infiltrating ductal carcinoma and axillary lymph node metastasis, bigger diameters of the primary tumors, later pTNM staging, and a lower incidence rate of ductal carcinoma in situ (p < 0.05). High expression of ER and PR led to fewer patients classified histologically in higher grade (p = 0.001), while high expression of Ki-67 and p53 caused more patients classified histologically in higher grade (p = 0.001). In patients histologically classified in grade 1 and 2, the expression of Ki-67 and p53 was significantly (p = 0.001) higher, and the expression of ER and PR was significantly lower, in Her-2 positive patients than Her-2 negative patients. Breast cancer with Her-2 overexpression was more likely to recur and metastasize than Her-2 negative breast cancer. Higher coincidence of high expression of p53 and Ki-67 with Her-2 overexpression and more progressed tumors suggested that in addition to p53, Ki-67 might also be a prognostic biomarker of breast cancer.

Entities:  

Keywords:  Her-2 overexpression; Ki-67; breast cancer; clinicopathologic characteristic; p53

Mesh:

Substances:

Year:  2017        PMID: 28075663      PMCID: PMC5553327          DOI: 10.1080/21655979.2016.1235101

Source DB:  PubMed          Journal:  Bioengineered        ISSN: 2165-5979            Impact factor:   3.269


  66 in total

Review 1.  Behind the scenes: unravelling the molecular mechanisms of p53 target gene selectivity (Review).

Authors:  Leonie Smeenk; Marion Lohrum
Journal:  Int J Oncol       Date:  2010-11       Impact factor: 5.650

2.  Correlation of the HER-2 protein expression and other clinicopathological features of ductal infiltrative breast cancer.

Authors:  Svjetlana Radović; Mirsad Babić; Mirsad Dorić; Edina Balta; Erol Kapetanović; Senad Secić
Journal:  Bosn J Basic Med Sci       Date:  2005-02       Impact factor: 3.363

3.  [Expression of Ki67 and clinicopathological features in breast cancer].

Authors:  Baona Wang; Xiang Wang; Jing Wang; Lixue Xuan; Zhongzhao Wang; Xin Wang; Jidong Gao; Haizeng Zhang
Journal:  Zhonghua Zhong Liu Za Zhi       Date:  2014-04

4.  Reply to Ki67 in breast cancer: a useful prognostic marker!

Authors:  C Denkert; G von Minckwitz
Journal:  Ann Oncol       Date:  2014-01-15       Impact factor: 32.976

5.  Chemotherapy response of breast cancer depends on HER-2 status and anthracycline dose intensity in the neoadjuvant setting.

Authors:  T Petit; C Borel; J P Ghnassia; J F Rodier; A Escande; R Mors; P Haegelé
Journal:  Clin Cancer Res       Date:  2001-06       Impact factor: 12.531

Review 6.  Intrinsically disordered proteins in cellular signalling and regulation.

Authors:  Peter E Wright; H Jane Dyson
Journal:  Nat Rev Mol Cell Biol       Date:  2015-01       Impact factor: 94.444

Review 7.  Best hope or last hope: access to phase III clinical trials of HER-2/neu for advanced stage breast cancer patients.

Authors:  B Strauss
Journal:  J Adv Nurs       Date:  2000-02       Impact factor: 3.187

Review 8.  Current and emerging breast cancer biomarkers.

Authors:  Maryam Sana; Hassan Jameel Malik
Journal:  J Cancer Res Ther       Date:  2015 Jul-Sep       Impact factor: 1.805

9.  Relationship between NF-κB, ER, PR, Her2/neu, Ki67, p53 expression in human breast cancer.

Authors:  D O Shapochka; S P Zaletok; M I Gnidyuk
Journal:  Exp Oncol       Date:  2012-12

10.  A clinical database of breast cancer patients reveals distinctive clinico-pathological characteristics: a study from central China.

Authors:  Lin-Wei Wang; Gui-Fang Yang; Jia-Mei Chen; Fang Yang; Jing-Ping Yuan; Sheng-Rong Sun; Chuang Chen; Ming-Bai Hu; Yan Li
Journal:  Asian Pac J Cancer Prev       Date:  2014
View more
  5 in total

1.  A comparison of Chinese multicenter breast cancer database and SEER database.

Authors:  Yingjie Niu; Fan Zhang; Dong Chen; Guolin Ye; Yong Li; Yong Zha; Wenlin Chen; Dequan Liu; Xiaoming Liao; Qinghua Huang; Wei Tang; Gengxi Cai; Rong Guo; Hongyang Li; Shicong Tang
Journal:  Sci Rep       Date:  2022-06-21       Impact factor: 4.996

2.  CCDC106 promotes the proliferation and invasion of ovarian cancer cells by suppressing p21 transcription through a p53-independent pathway.

Authors:  Na Zhao; Chen Wang; Peng Guo; Jun Hou; Hong Yang; Ting Lan; Yehan Zhou; Jiayu Li; Ujjal K Bhawal; Yang Liu
Journal:  Bioengineered       Date:  2022-04       Impact factor: 6.832

3.  ZIC1 acts a tumor suppressor in breast cancer by targeting survivin.

Authors:  Wei Han; Fang Cao; Xiao-Jiao Gao; Hua-Bing Wang; Fang Chen; Si-Jian Cai; Cong Zhang; Yong-Wei Hu; Jun Ma; Xing Gu; Hou-Zhong Ding
Journal:  Int J Oncol       Date:  2018-06-21       Impact factor: 5.650

4.  Tumor-associated neutrophils activated by tumor-derived CCL20 (C-C motif chemokine ligand 20) promote T cell immunosuppression via programmed death-ligand 1 (PD-L1) in breast cancer.

Authors:  Louis Boafo Kwantwi; Shujing Wang; Wenjun Zhang; Weidong Peng; Zeyu Cai; Youjing Sheng; Han Xiao; Xian Wang; Qiang Wu
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

5.  Associations of Estrogen Receptor, Progesterone Receptor, Human Epidemic Growth Factor Receptor-2 and Ki-67 with Ultrasound Signs and Prognosis of Breast Cancer Patients.

Authors:  Xingjuan Zhao; Xuan Yang; Lei Fu; Keda Yu
Journal:  Cancer Manag Res       Date:  2021-06-09       Impact factor: 3.989

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.